Zacks Investment Research
21 Jul 2026, 14:55 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Wall Street analysts have a mean short-term price target for Tenax Therapeutics (TENX) of $34.71, implying a potential upside of 121.4% from its current price of $15.68. — A significant positive gap between the current price and the consensus target typically attracts bullish momentum and buyer interest.
+0.60Analysts are revising their earnings estimates for Tenax Therapeutics upward, indicating expectations for better-than-previously-estimated performance. — Positive earnings revisions are a strong fundamental signal that often precedes price increases.
+0.40Tenax Therapeutics shares have gained 28% over the past four weeks. — Recent price appreciation confirms existing positive sentiment and upward momentum for the stock.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The stock has gained 28% recently and has a significant analyst-projected upside of 121.4% with positive earnings revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
